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Abstract
Background: 'Cognitive Behavioral Analysis System of Psychotherapy' (CBASP) is a form of psychotherapy specifically
developed for patients with chronic depression. In a study in the U.S., remarkable favorable effects of CBASP have been
demonstrated. However, no other studies have as yet replicated these findings and CBASP has not been tested outside the
United States. This protocol describes a randomized controlled trial on the effectiveness of CBASP in the Netherlands.
Methods/Design: The purpose of the present paper is to report the study protocol of a multisite randomized controlled trial
testing the effectiveness of 'Cognitive Behavioral Analysis System of Psychotherapy' (CBASP) for chronic depression in the
Netherlands. In this study, CBASP in combination with medication, will be tested versus usual secondary care in combination
with medication. The aim is to recruit 160 patients from three mental health care organizations. Depressive symptoms will be
assessed at baseline, after 8 weeks, 16 weeks, 32 weeks and 52 weeks, using the 28-item Inventory for Depressive
Symptomatology (IDS). Effect modification by co morbid anxiety, alcohol consumption, general and social functioning and
working alliance will be tested. GEE analyses of covariance, controlling for baseline value and center will be used to estimate the
overall treatment effectiveness (difference in IDS score) at post-treatment and follow up. The primary analysis will be by
'intention to treat' using double sided tests. An economic analysis will compare the two groups in terms of mean costs and cost-
effectiveness from a societal perspective.
Discussion: The study will provide an answer to the question whether the favorable effects of CBASP can be replicated outside
the US.
Trial Registration: The Dutch Cochrane Center, NTR1090.
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According to the World Health Organization, Major
Depressive Disorder (MDD) is the second largest health-
care problem worldwide in terms of limitations caused by
illness [1]. MDD causes high rates of subjective suffering,
absenteeism and utilization of medical services [2]. Both
in the Netherlands and elsewhere it was found that 20%
of depressions still persist after two years [3,4]. Chronic
MDD causes a greater illness burden, more suicide
attempts and more hospital admissions compared to
acute MDD [5,6]. In outpatient mental health popula-
tions, chronic MDD affects an estimated 25–35% of
depressive patients [7,8]. Unfortunately, the treatment
results for this group of depressed patients are often disap-
pointing and the existing treatment protocols are insuffi-
ciently tailored to chronic MDD [9]. For this reason, an
effective psychotherapeutic treatment will constitute a
welcome addition to the range of treatments currently
available for chronically depressed patients.
Although there is a reasonably large body of literature
evaluating cognitive as well as interpersonal therapy for
nonchronic or mixed depressed samples, few studies have
specifically investigated the group of chronically
depressed patients [10]. A study that did target this group
of patients examined the effectiveness of 'Cognitive
Behavioral Analysis System of Psychotherapy' (CBASP), a
form of psychotherapy that was specifically developed for
chronic depression. CBASP's core procedure is called "sit-
uational analysis", a highly structured technique that
teaches chronically depressed patients to fix their prob-
lematic interpersonal encounters. It is designed to teach
patients that their behavior has consequences (called per-
ceived functionality) by focusing on situational conse-
quences to change their thoughts and behavior. CBASP
conceptualizes that the interpersonal difficulties these
patients encounter outside the therapy are also likely to
emerge in the therapeutic relationship [11]. These difficul-
ties are anticipated through "transference hypotheses" for-
mulated early in treatment, which helps the therapist to
recognize and resolve therapeutic impasses [9,12].
In a multisite trial involving 681 patients suffering from
chronic depression, Keller and colleagues [13] compared
the efficacy of an antidepressant (nefazodone), CBASP
alone and their combination. After 12 weeks of treatment
CBASP alone was equally effective as nefazodone alone
[response rate of 48%]. The combination of nefazodone
and CBASP was the most effective treatment [response
rate of 73%]. After four months continuation treatment
the authors found no difference between nefazodone and
CBASP and found an ongoing advantage for combined
treatment. Furthermore, over 85% of responders after 12
weeks of treatment maintained that response in continu-
ation [14]. After 52 weeks of treatment, it was also found
that CBASP was effective as a maintenance treatment for
chronic depression [15].
In addition, it was found that CBASP was a good alterna-
tive for patients who were not motivated for, or refractory
to medical treatment. For the non-responders in the study
it was found that the switch from nefazodone to CBASP
and vice versa resulted in clinically and statistically signif-
icant improvements [16,17].
As a result of these findings, CBASP is mentioned as an
evidence based treatment option for chronic depression
in the Dutch treatment guidelines [18]. However, the
results of the American study have not yet been replicated.
In addition, the dissemination of CBASP outside the US is
limited. In order to test whether these findings can be rep-
licated in a Dutch population we designed a randomized
controlled trial on the effectiveness of CBASP. Our
research questions are:
1. Is CBASP more effective and cost-effective than usual
secondary care?
2. Which patient related factors predict a beneficial
response?
Methods/Design
Study design
This study is a multi-center randomized controlled trial in
which the effects of CBASP will be evaluated. CBASP, in
combination with antidepressant treatment, will be tested
versus usual secondary care in combination with antide-
pressant treatment over 52 weeks follow-up. The aim is to
establish the clinical and cost effectiveness of CBASP plus
antidepressant treatment in secondary care.
Recruitment/Settings and locations
Patients will be recruited within the mood disorder
departments of three organizations for mental health care
in Amsterdam and The Hague. All newly registered
patients will first be seen by a psychologist or psychiatrist
for an intake and screening interview, which is part of a
standard procedure. After the intake procedure patients'
diagnosis and indication will be discussed in a staff meet-
ing. At each site, the research-coordinator of the study will
attend the staff meetings to select the patients diagnosed
with chronic depression. These patients will be
approached for participation in the study. The coordina-
tor will be screening the patients on the inclusion-exclu-
sion criteria of this study and inform them about the
study. If patients are willing and eligible to participate,
written informed consent will be elicited. The inclusion
period will cover one year.Page 2 of 8
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Inclusion criteria
Patients (aged 18–65) are eligible to participate if their
main diagnosis is a chronic form of depression according
the DSM-IV criteria: a) a chronic major depressive disor-
der (i.e. existing for longer than 2 years) or b) a major
depressive disorder superimposed on a dysthymic disor-
der or c) a recurrent major depressive disorder which, in
the past 2 years, never fully remitted between the epi-
sodes. The Mini International Neuropsychiatric Interview
plus (M.I.N.I. plus), a structured diagnostic interview
developed in 1990 by psychiatrists and clinicians in the
United States and Europe for DSM-IV and ICD-10 psychi-
atric disorders, will be used to assess chronic depression
[19,20]. In addition, the level of symptom severity should
be moderate to severe, expressed as a score of 22 or more
on the 28-item Inventory for Depressive Symptomatology
(IDS) [21,22].
Exclusion criteria
Patients are excluded from the study if: a) they suffer from
one (or more) of the following disorders: a psychotic dis-
order, bipolar disorder, organic brain syndrome, sub-
stance dependence, or a severe borderline -, schizotypical
-, or antisocial personality disorder or b) they have high
risk of suicide c) they do not have sufficient command of
the Dutch language necessary to participate in the study.
Randomization
After signing the informed consent form, patients will
enroll in the study and start with the baseline interview.
After completing the baseline interview, patients will be
assigned at random to either the intervention group or the
control group. The intervention group will receive CBASP,
while the control group will receive treatment as usual.
Randomization will be performed by an external
researcher using a computerized random number genera-
tor. Randomization is stratified per location.
Assessments
Data are collected at five points in time: at baseline (T0),
after 8 weeks of treatment (T1), after 16 weeks of treat-
ment (T2), after 32 weeks of treatment (T3), and at the
endpoint, after 52 weeks of treatment (T4). The Quick
Inventory of Depressive Symptomatology self-report [23]
will be assessed monthly. Table 1 summarizes the meas-
ures that are used at each point. The assessments will be
performed by an experienced research nursing staff. At
baseline and endpoint there will be a face-to-face inter-
view besides the written questionnaires; the three assess-
ments in between consist of written questionnaires only.
The research nursing staff from the three participating
organizations will participate in a two-day training course
to make sure the measures are conducted the same way at
the different locations.
Outcome measures
Primary outcome measure
The primary outcome measure is the reduction of depres-
sive symptoms measured with the 28-item version of
Inventory of Depressive Symptoms (IDS). The IDS is a
measure of symptom severity in depression that has been
used to assess acute and longer-term outcomes and has
highly acceptable psychometric properties (Cronbach's
alpha = .92) [21,22]. The IDS self-report version will be
administered at baseline, after 8, 16 and 32 weeks and at
the end of the study, at 52 weeks follow-up. Patients with
a 50% symptom reduction on the IDS, are responders
[13]. Remission is defined as an IDS score of 13 or less.
Secondary measures of outcome/predictors of response
To assess chronic depression and co morbid disorders at
baseline and at the end of the study patients will receive a
diagnostic interview using the M.I.N.I. plus [19,20].
Information on demographic factors (age, gender, marital
status, education, professional occupation) will be col-
lected in the baseline interview and at the end of the
study.
Putative modifiers of effect are well known risk-factors for
chronic depression [24], these are: level of functioning,
which will be measured using the WHODAS [25], social
contacts and social participation using the Loneliness &
Affiliation Scale [26] and the Social Participation Scale
[27], locus of control using the Mastery Scale [28] and
psychological well being using the Psychological Well
Being Scales (PWB) [29]. Physical health and diseases will
be measured by a validated Dutch questionnaire [30],
psychological mindedness using the Lack of Psychological
Mindedness (LPM) [31] and parental relationship using
the Remembered Parenting Scale (RRP) [31]. The Mood
Disorder Questionnaire (MDQ) [32] will be used to meas-
ure bipolar symptoms, number of depressive episodes in
the past five years using the Life Chart [33], anxiety using
the Beck Anxiety Inventory (BAI) [34], alcohol depend-
ence using the Alcohol Use Disorders Identification Test
(AUDIT) [35], recent trauma using the Brugha question-
naire [36] and childhood trauma using the Nemesis ques-
tionnaire [37]. Personality will be measured using the
NEO-Five Factor Inventory (NEO-FFI) [38] and working
alliance using the Working Alliance questionnaire [39].
All measures of outcomes are widely used internationally,
are reliable and valid, also for usage in the Netherlands.
Interventions
For this project 'the founder' of CBASP, J.P. McCullough
Jr., came to Amsterdam to train the 25 therapists partici-
pating in this study. A four day workshop was given dur-
ing which the basic techniques of CBASP were taught. FivePage 3 of 8
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by McCullough in the US to become CBASP Supervisors.
They will supervise the participating therapists during the
study. The therapy will be carried out as specified in the
CBASP protocol [40-42]. The treatment protocol for the
therapists and manual for the patients have been trans-
lated into Dutch. All therapists have to treat two patients
under supervision before being allowed to treat patients
in the study. All CBASP sessions will be audio taped, and
the supervisors will review the audiotapes to assess the
psychotherapists' adherence to the treatment procedures
(McCullough, Jr. J.P. (1995). Adherence Scale. Unpub-
lished Scale. Richmond, VN: Virginia Commonwealth
University). Supervision will be given on a weekly basis.
CBASP
The central idea of CBASP is that chronically depressed
patients fail to recognize the connection between their
behavior and interpersonal/environmental consequences.
In other words, they do not grasp their own contribution
to the life difficulties they encounter. The major goals of
CBASP are to help patients 1) to understand the conse-
quences of their behavior, 2) to change their patterns of
coping, and 3) to improve their interpersonal skills [9].
Table 1: Summary of measures
Measure Baseline 8 week follow-up 16 week follow-up 32 week follow-up 52 week follow-up
Interview:
Mini plus measures diagnostics x x
Demographics x x
CBS questionnaire measures physical health x x
LIFE-CHART measures duration of 
depression
x
NEMESIS questionnaire of childhood 
trauma
x
Brugha questionnaire of recent life events x x
Self report measurements:
Inventory of Depressive Symptoms (IDS) x x x x x
Quick Inventory of Depressive Symptoms 
(QIDS)
Monthly assessment
Beck's Anxiety Inventory (BAI) x x x x x
AUDIT measure of alcohol consumption x x x x x
Working alliance questionnaire-patient 
version
x x x
Mastery scale measures locus of control x x x x x
Social activity/participation x x x x x
WHODAS x x x x x
Loneliness & Affiliation Scale x x
NEO-Five Factor Inventory x x
Mood Disorder Questionnaire x x
Psychological Well Being (PWB) x x
Lack of Psychological Mindedness (LPM) x x
Remembered Parenting Scale (RRP) x
Questionnaires for economic 
evaluation:
Registration of usage medication x x
TIC-P measures illness and work x x
Perceived need for care x x
TIC-P work + health care utalization self 
report
x x
Questionnaires filled in by therapists: Baseline 8 week follow-up 16 week follow-up 32 week follow-up 52 week follow-up
Clinical Global Impression-Improvement 
(CGI)
x x x x
Working alliance questionnaire, therapist 
version
x x xPage 4 of 8
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problem skills, and makes use of regular homework
assignments. The main focus is on interpersonal problems
with significant others, but also in the therapist-patient
relationship. The relationship with the therapist is used as
a tool to help patients to become more aware of their
impact on others and to distinguish between adaptive and
maladaptive relationships [9].
CBASP consists of a total of 26–30 sessions in a period of
a year. CBASP starts with bi-weekly sessions in the first 4
weeks followed, in principle, by one session per week
from week 5–16. If establishing the therapeutic relation-
ship proves particularly difficult, the two-weekly sessions
can be prolonged for four more weeks. After 16 weeks
(16–20 sessions), 4 sessions will be given once every two
weeks during weeks 17–25, and as a maintenance treat-
ment there will be 6 monthly sessions of CBASP during
weeks 26–52.
Treatment as usual
At the three sites, treatment as usual is based on the exist-
ing Dutch multidisciplinary guidelines for depression
[18]. This means that, besides optimal medical care, treat-
ment as usual can consists of evidence-based psychother-
apies, such as Cognitive Behavioral Therapy,
Interpersonal Psychotherapy, or Short Psychoanalytic
Supportive Psychotherapy [43]. Other interventions that
may be part of the treatment offered for chronically
depressed patients are supportive or structured activities
and treatments that focus on relaxation, assertiveness,
running, or other tasks. The treatment package received by
patients in the treatment-as-usual condition will be regis-
tered throughout the study.
Pharmacotherapy
In both conditions drug treatment will be given, consist-
ing of guideline' driven antidepressant medication [18].
The pharmacotherapy will be supported by 'clinical man-
agement' [44]: brief sessions in which patients will be
informed about the importance of adherence and the
effects and side effects of medication. The psychiatrist will
change the dose or medication when necessary. The use of
medication (name, dose given, and blood levels if availa-
ble) will be registered for all patients participating in the
study. Patients who refuse to use medication will not be
excluded, because CBASP has also been found to be effec-
tive as a monotherapy for chronically depressed patients
[13].
Economic evaluation
An economic evaluation will be performed from a societal
public health perspective. All direct and indirect costs will
be taken into account. Both direct costs within the health
care system (e.g., costs of visits to GP, specialist, and ther-
apist, hospital admissions, and medication use) and
direct costs outside the health care system (e.g., costs of
self medication, consultations with complementary med-
icine, and informal care) will be measured and valued. All
direct costs will be considered because it is difficult to dis-
cern which costs are associated with the depressive disor-
der and which not. The cost-price of the CBASP
intervention will be assessed using the bottom-up
method. Data on health care utilization and work absen-
teeism are collected by the Perceived Need for Care ques-
tionnaire (PNCQ) [45] and the Trimbos/iMTA
questionnaire for Costs associated with Psychiatric Illness
(TIC-P) [46], which patients will fill out four times during
the study, at baseline, after 16 weeks, after 32 weeks and
at the end of the study, after 52 weeks. Medicine utiliza-
tion will be registered at baseline and during the study
until the end. Costs of health care utilization will be cal-
culated using cost prices, if available. Otherwise tariffs will
be used. Indirect costs will be calculated using the friction
cost method.
Sample size
Based on the findings of the study of Keller and colleagues
[13] it is estimated that the addition of CBASP to the exist-
ing treatment will lead to 25% more response in the inter-
vention condition compared to the control condition. To
demonstrate this difference 60 patients in each condition
(beta 0.80 and alpha 0.05) are necessary [47]. Assuming a
drop-out percentage of 25%, this means that 160 partici-
pants need to be recruited.
Analysis
Analysis of covariance, controlling for baseline value will
be used to estimate the overall treatment effectiveness
(difference in IDS score) at follow-up. The primary analy-
sis will be by 'intention to treat' using double sided tests.
Further exploratory analyses will also assess the impact of
other explanatory factors and will model the time course
of effects using the 16-week and 32-week measurements
in a panel analysis. Sensitivity analyses will include esti-
mating 'on treatment' effects, CACE (complier average
causal effects), and imputation of any missing values.
More sophisticated techniques will be used, like GEE anal-
ysis, to measure the longitudinal effects.
The main aim of the economic analysis is to compare the
two groups in terms of mean costs and cost-effectiveness.
Analysis will be performed according to intention-to-treat
principle. The primary outcome measure of the study will
be included in the cost-effectiveness ratios. Cost-effective-
ness ratios and cost-utility ratios will be calculated using
bootstrapping techniques according to the bias corrected
percentile method. Bootstrapped cost-effect pairs will be
graphically represented on a cost-effectiveness plane. Sen-
sitivity analyses will be performed to study variations inPage 5 of 8
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contribute to the total costs.
Ethical principles
The participation in the study is voluntary. Participants
are informed that they can cancel their participation at
any time without disclosing reasons for their cancellation
and without negative consequences for their future care.
Participants will sign an informed consent.
Vote of the ethics committee
The design and conduct of the study was approved by the
Medical Ethics Committee of the VU University Medical
Center, Amsterdam.
Discussion
This study protocol is presented here to offer researchers
the opportunity to consider the methodological quality of
this study with a critical view. Therapists can benefit by
considering the information regarding the practical appli-
cations of the proposed protocol on chronically depressed
patients in secondary care.
The number of studies examining the effects of psycho-
therapy on chronically depressed patients is very small,
while chronic depression affects a large group of patients
in secondary care and this subgroup is notable for poorer
subjective well being and impaired social and occupa-
tional functioning compared to non-chronically
depressed patients [10]. Research into the effectiveness of
CBASP can make an important contribution to the
improvement of care for chronically depressed patients.
According to the results of Keller et al. (2000), 73% of
these patients can be effectively treated if CBASP is com-
bined with antidepressant medication. CBASP can also be
an alternative for patients who are not motivated for or
refractory to pharmacological treatment. Furthermore,
CBASP could also be effective as a maintenance treatment
[13-17].
Strengths and limitations
Many methodological requirements for a high quality
trial are met. Allocation is concealed through randomiza-
tion by an external researcher. Recruitment of the patients
will be done after the standard intake procedure at each
site. As this study takes place within the mood disorder
departments of three organizations for mental health care
in the Netherlands the results can, to a large extent, be
generalized to the population of chronically depressed
patients seen in secondary care in the Netherlands.
A limitation of the present study is that the assessments
will be performed by research nursing staff who cannot be
kept blind to the treatment condition of the included
patients, as is always the case in trials studying the effects
of psychotherapy. Nor are the patients blind to treatment
condition. In this study, however, the main outcome
measures are self-report questionnaires, which means that
they will not be influenced by the research nursing staff.
Timeframe of the study
In October 2006 a pilot study, supervised by McCullough,
has started to enable the therapists to gain experience with
this innovative intervention. In May 2007 the randomized
treatment study has been started up. Month 1–12: Screen-
ing and inclusion of chronically depressed patients at the
three locations. Start of the data collection for the treat-
ment study. Supervision of the treatments. Start of data
entry and purging of databases. Month 13–24: Comple-
tion of data collection. Completion of purging and analy-
sis of the data. Publication on these short-term findings.
Month 24–36: Completion of data collection of the fol-
low-up. Publication on the effectiveness of CBASP and the
follow-up effects. Dissemination of the results (e.g. pres-
entation of study results at national and international
conferences). Working on the implementation of CBASP
in the Netherlands.
Description of risks
There are no specific risks related to this study.
shows the procedures in a flow chartFigure 1
shows the procedures in a flow chart.
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